Exemestane (Aromasin), tamoxifen (Nolvadex, generic) and raloxifene (Evista) are three drugs used to prevent breast cancer in postmenopausal women who are at elevated risk for the disease. Exemestane appears to have less frightening side effects — hot flashes, joint pain, and loss of bone density.
All three of these drugs target estrogen, which fuels the growth of most breast cancers, but exemestane belongs to a different class of drugs, called aromatase inhibitors, which work by blocking the body's production of estrogen.
Previous studies have shown that aromatase inhibitors are more effective than tamoxifen in preventing breast cancer from recurring. This study, funded Pfizer, and conducted under the auspices of the National Cancer Institute's clinical trials unit, looked at whether exemestane could reduce the likelihood of a first occurrence of breast cancer.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.